Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00323011
Status:
TERMINATED
Last Update Posted:
2014-05-21
First Post:
2006-05-05
Brief Title:
FOLFIRI Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
drug not available
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for people with colorectal cancer who have tumors that cannot be completely removed by surgery Blood clots are a problem in patients with cancer Blood clots are also a problem in patients receiving cancer drugs Studies have shown that up to 17 of patients receiving cancer drugs experienced blood-clotting problems One purpose of this study is to find if the drug combination of irinotecan 5-fluorouracil 5-FU bevacizumab and leucovorin LV affect blood-clotting factors A second purpose of this study is to find out what effects the drug dalteparin has on clotting factors in the blood in patients receiving the drug combination of irinotecan 5-FU bevacizumab and LV It is hoped that adding dalteparin to chemotherapy may benefit patients with colorectal cancer by preventing blood clots
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None